Moderna, Inc.
MRNANASDAQHealthcareBiotechnology

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Company Information

CEOStéphane Bancel
Founded2010
IPO DateDecember 7, 2018
Employees5,800
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone617 714 6500
Address
325 Binney Street Cambridge, Massachusetts 02142 United States

Corporate Identifiers

CIK0001682852
CUSIP60770K107
ISINUS60770K1079
EIN81-3467528
SIC2836

Leadership Team & Key Executives

Stéphane Bancel
Chief Executive Officer and Director
Dr. Stephen Hoge M.D.
President
James M. Mock
Chief Financial Officer
Shannon Thyme Klinger J.D.
Chief Legal Officer and Corporate Secretary
Dr. Jerh Collins Ph.D.
Chief Technical Operations and Quality Officer
Lavina Talukdar CFA
Senior Vice President and Head of Investor Relations
Tracey Franklin
Chief People and Digital Technology Officer
Dr. Melanie Ivarsson M.B.A., O.B.E., Ph.D.
Chief Development Officer
Dave Johnson
Chief Data and AI Officer
Dr. Charbel Haber M.P.H., Ph.D.
Senior Vice President and Head of Global Regulatory Science